BRCA1 and ovarian cancer: BRCA reversion mutations, frequently involving deletions of <100 bp, restore the open reading frame of BRCA1/2 and can be detected in circulating cell-free DNA, providing a minimally invasive method to monitor treatment effectiveness and guide further interventions in ovarian cancer [34].